Business
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain ThresholdsMIAMI, FL / ACCESSWIRE / August 26, 2024 /
About this update from Mira Pharmaceuticals, Inc.
[{"type":"text","content":"Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain ThresholdsMIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is proud to announce a major breakthrough in the treatment of neuropathic pain. A recent pre-clinical study in rats demonstrated that its novel oral ketamine analog, Ketamir-2, produced a significant reversal of neuropathic pain, induced by nerve ligation, culminating in a 100% normalization of pain thresholds at the highest dose. This effect stands in stark contrast to traditional ketamine, which proved ineffective orally under the same experimental conditions.The study, conducted at Pharmaseed Ltd, utilized a nerve ligation model to replicate human neuropathic pain and specifically investigates mechanical allodynia. The results were compelling: low oral doses of Ketamir-2 led to a significant reversal of pain for 14 and 22 days following the operation. At higher oral dose, Ketamir-2 achieved complete normalization of the pain threshold, representing a 100% reversal of the neuropathic pain signal. These outcomes underscore Ketamir-2's superior efficacy and highlight its potential as a transformative treatment for neuropathic pain, especially compared to oral ketamine, which did not deliver significant pain relief.In light of this compelling data, MIRA Pharmaceuticals is conducting additional studies to evaluate Ketamir-2's efficacy in treating cancer-induced depression and neuropathic pain. These studies aim to explore cancer-related indications, which could pave the way for faster regulatory approvals and innovative clinical study designs. MIRA is optimistic that these efforts could demonstrate efficacy in humans as early as 2025.\"The development of Ketamir-2 as an oral treatment for neuropathic pain is a significant milestone not only for MIRA but for the entire field of neuropsychiatric and neurologic disorder therapies,\" said Erez Aminov, Chairman and CEO of MIRA Pharmaceuticals. \"Neuropathic pain is a debilitating condition that imposes an enormous burden on patients, often leaving them with limited and ineffective treatment options. These findings suggest that Ketamir-2 could offer patients a more accessible, safer, and effective treatment option, potentially...